| Primary information |
|---|
| ID | 1449 |
| ThPP ID | Th1081 |
| Therapeutic Peptide/Protein Name | Antithymocyte globulin |
| Sequence | N.A. view full sequnce in fasta |
| Functional Classification | IIa |
| Molecular Weight | N.A. |
| Chemical Formula | N.A. |
| Isoelectric Point | N.A. |
| Hydrophobicity | N.A. |
| Melting Point (℃) | 61 (FAB fr |
| Half Life | 2-3 days |
| Description | Polyclonal rabbit anti-thymocyte globulin. Used to suppresses certain types of immune cells ascribed to acute organ rejection in transplant patients by selective depletion of T-cells. |
| Indication/Disease | For prevention of renal transplant rejection |
| Pharmacodynamics | Antithymocyte Globulin (ATG)is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts. |
| Mechanism of Action | Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis. |
| Toxicity | N.A. |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. |
| Absorption | N.A. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | Immunologic Factors and Immunosuppressive Agents |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | Canakinumab results in increased immunosuppressive effects; increases the risk of infection |
| Target | N.A. |
| Information of corresponding available drug in the market |
|---|
| Brand Name | Antithymocyte globulin |
| Company | Pfizer |
| Brand Discription | Treating acute kidney transplant rejection with other medicines used to suppress the immune system. It may also be used for other conditions as determined by your doctor. Anti-thymocyte globulin (rabbit) is an immune globulin. It works by suppressing the body's immune response, but the way it does this is not fully understood. |
| Prescribed for | N.A. |
| Chemical Name | N.A. |
| Formulation | Powder for injection 25 mg vials |
| Physcial Appearance | N.A. |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | Usual Adult Dose for Renal Transplant: 1.5 mg/kg/day by IV infusion for 7 to 14 days. Anti-thymocyte globulin (rabbit) should be infused over a minimum of 6 hours for the first infusion and over at least 4 hours on subsequent days of therapy. Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to the infusion is recommended and may reduce the incidence and intensity of side effects during the infusion. |
| Contraindication | Acute viral illness; hypersensitivity to leporine proteins; previous hypersensitivity to anti-thymocyte globulin. |
| Side Effects | N.A. |
| Useful Link | N.A. |
| PubMed ID | 25598277, 25588925, 25583265, 25563075, 25539464, 25536216, 12160363 |
| 3-D Structure | N.A. |